Remdesivir for the Prevention of Invasive Mechanical Ventilation or Death in Coronavirus Disease 2019 (COVID-19): A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-1 Cohort Data.
Author
Paules, Catharine IGallagher, Shannon K
Rapaka, Rekha R
Davey, Richard T
Doernberg, Sarah B
Grossberg, Robert
Hynes, Noreen A
Ponce, Philip O
Short, William R
Voell, Jocelyn
Wang, Jing
Yang, Otto O
Wolfe, Cameron R
Lye, David C
Dodd, Lori E
Benson, Constance A
Date
2022-04-09Journal
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of AmericaPublisher
Oxford University PressType
Article
Metadata
Show full item recordAbstract
This post hoc analysis of the Adaptive Coronavirus Disease 2019 (COVID-19) Treatment Trial-1 (ACTT-1) shows a treatment effect of remdesivir (RDV) on progression to invasive mechanical ventilation (IMV) or death. Additionally, we create a risk profile that better predicts progression than baseline oxygen requirement alone. The highest risk group derives the greatest treatment effect from RDV.Rights/Terms
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.Identifier to cite or link to this item
http://hdl.handle.net/10713/18680ae974a485f413a2113503eed53cd6c53
10.1093/cid/ciab695
Scopus Count
Related articles
- Remdesivir Treatment in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19): A Comparative Analysis of In-hospital All-cause Mortality in a Large Multicenter Observational Cohort.
- Authors: Mozaffari E, Chandak A, Zhang Z, Liang S, Thrun M, Gottlieb RL, Kuritzkes DR, Sax PE, Wohl DA, Casciano R, Hodgkins P, Haubrich R
- Issue date: 2022 Aug 24
- Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.
- Authors: Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Poissy J, Belhadi D, Diallo A, Lê MP, Peytavin G, Staub T, Greil R, Guedj J, Paiva JA, Costagliola D, Yazdanpanah Y, Burdet C, Mentré F, DisCoVeRy Study Group.
- Issue date: 2022 Feb
- Deconstructing the Treatment Effect of Remdesivir in the Adaptive Coronavirus Disease 2019 (COVID-19) Treatment Trial-1: Implications for Critical Care Resource Utilization.
- Authors: Fintzi J, Bonnett T, Sweeney DA, Huprikar NA, Ganesan A, Frank MG, McLellan SLF, Dodd LE, Tebas P, Mehta AK
- Issue date: 2022 Jul 6
- Compassionate Use of Remdesivir for Patients with Severe Covid-19.
- Authors: Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure FX, Nicastri E, Oda R, Yo K, Quiros-Roldan E, Studemeister A, Redinski J, Ahmed S, Bernett J, Chelliah D, Chen D, Chihara S, Cohen SH, Cunningham J, D'Arminio Monforte A, Ismail S, Kato H, Lapadula G, L'Her E, Maeno T, Majumder S, Massari M, Mora-Rillo M, Mutoh Y, Nguyen D, Verweij E, Zoufaly A, Osinusi AO, DeZure A, Zhao Y, Zhong L, Chokkalingam A, Elboudwarej E, Telep L, Timbs L, Henne I, Sellers S, Cao H, Tan SK, Winterbourne L, Desai P, Mera R, Gaggar A, Myers RP, Brainard DM, Childs R, Flanigan T
- Issue date: 2020 Jun 11
- A Review on Remdesivir: A Broad-spectrum Antiviral Molecule for Possible COVID-19 Treatment.
- Authors: Khazir J, Maqbool T, Mir BA
- Issue date: 2021